I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Archive

Access the archives to find the information you want

No results found

Sign up or login to unlock the full suite of MEDICALLY features

Dec 13 / Roche and Genentech
Lower total cost of care with mosunetuzumab compared with alternative novel treatment options in third-line or later relapsed/refractory follicular lymphoma: a United States third-party payer perspective
A micro-economic analysis was conducted to evaluate the total cost of care of mosunetuzumab compared with alternative novel treatment options in patients with third-line or later relapsed/refractory follicular lymphoma. Comparisons of the total cost of care of these therapies from a United States third-party payer perspective are presented.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 13 / Roche and Genentech
Mosunetuzumab is cost-effective compared with alternative novel treatment options in patients with third-line or later relapsed/refractory follicular lymphoma over a long-term horizon in the United States
A cost-effectiveness analysis was conducted, using a simulated partitioned survival model with health states of progression-free survival, post-progression survival, and death, to compare mosunetuzumab with alternative treatment options. The cost-effectiveness of these therapies from a United States payer perspective are presented.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 13 / Roche and Genentech
The global failure of mammography screening accessibility - a systematic literature review
Disparities in breast cancer (BC) outcomes between high-income and low-income countries result from social determinants and limited access to mammography screening, leading to later diagnoses and poorer prognoses. Understanding and addressing the barriers to BC care are critical for improving clinical outcomes and achieving the World Health Organization's 2021 Global Breast Cancer Initiative ambition (to reduce BC mortality by implementing early detection, timely diagnosis, and comprehensive BC management). This poster presents the findings from a systematic literature review of the barriers that women face in accessing mammography screening, diagnosis, and BC treatment. An estimation of the number of women worldwide affected by delays or lack of access to medical services is also reported.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 12 / Roche and Genentech
Strength of patient preference for atezolizumab subcutaneous vs intravenous for the treatment of NSCLC and subgroup exploratory analyses from the IMscin002 study
IMscin002: Exploratory analyses from the IMscin002 trial exploring patient strength of preference for atezolizumab subcutaneous vs intravenous for the treatment of NSCLC, according to baseline characteristics, number of injections, and injection duration.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 12 / Roche and Genentech
ZN-1041, a potential best-in-class BBB Penetrable HER2 Inhibitor, has high antitumor activity in patients with Breast Cancer with CNS Metastases
This poster presents Phase Ic data evaluating the safety and efficacy of ZN-1041 in combination with trastuzumab and capecitabine, for the treatment of Chinese patients with HER2+ breast cancer brain metastases and extracranial disease.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 12 / Roche and Genentech
SKYSCRAPER-06: EFFICACY AND SAFETY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Efficacy and safety of tiragolumab + atezolizumab + chemotherapy vs pembrolizumab + chemotherapy in patients with advanced non-squamous NSCLC from the Phase 2/3 SKYSCRAPER-06 study.